BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Witthoeft T, Fuchs M, Ludwig D. Recent IV-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: An open-label pilot study. World J Gastroenterol 2007; 13(4): 579-584 [PMID: 17278224 DOI: 10.3748/wjg.v13.i4.579]
URL: https://www.wjgnet.com/1007-9327/full/v13/i4/579.htm
Number Citing Articles
1
April M. Young, Richard A. Crosby, Carrie B. Oser, Carl G. Leukefeld, Dustin B. Stephens, Jennifer R. Havens. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural AppalachiaJournal of Medical Virology 2012; 84(9): 1376 doi: 10.1002/jmv.23252
2
Kenneth Freedman, Jay Nathanson. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disordersExpert Review of Anti-infective Therapy 2009; 7(3): 363 doi: 10.1586/eri.09.1
3
Andrea K Erickson, Scott Seiwert, Michael Gale. Antiviral Potency Analysis and Functional Comparison of Consensus Interferon, Interferon-α2a and Pegylated Interferon-α2b against Hepatitis C virus InfectionAntiviral Therapy 2008; 13(7): 851 doi: 10.1177/135965350801300706
4
Karin Neukam, Juan Macías, José A Mira, Juan A Pineda. A review of current anti-HCV treatment regimens and possible future strategiesExpert Opinion on Pharmacotherapy 2009; 10(3): 417 doi: 10.1517/14656560802694481
5
Brian B. Gowen, Min-Hui Wong, Kie-Hoon Jung, Lawrence M. Blatt, Robert W. Sidwell. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1Antiviral Research 2008; 77(3): 215 doi: 10.1016/j.antiviral.2007.12.002